SoftBank’s Vision Fund 2 led a $59.7m round which will support Aculys in bringing a sleep disorder medication it has licensed to Japan.
Japan-based sleep disorder treatment provider Aculys Pharma has received $59.7m in a funding round led by internet and telecommunications group SoftBank’s Vision Fund 2, Nikkei has reported.
Sumitomo Mitsui Trust Investment, Catalys Pacific, HBM Healthcare Investments Anri and Global Founders Capital also participated in the round, which ostensibly marked the first time Vision Fund 2 has invested in a company headquartered in Japan.
Founded in January this year, Aculys Pharma aims to bring sleep a disorder medication that has already…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
